Development of Drug for Ulcerative Colitis to Be Discontinued, Company Reports

Development of Drug for Ulcerative Colitis to Be Discontinued, Company Reports
Belgium-based Galapagos NV has announced it is discontinuing its clinical development of drug candidate GLPG1205 for ulcerative colitis because an important part of the clinical trial -- endpoints for efficacy -- were not met. The ORIGIN Phase 2a clinical trial with GLPG1205 in patients with ulcerative colitis received good feedback on pharmacokinetics, tolerability, and safety, the company reported in a press release. But the important efficacy endpoints of the trial were not met, leading Galapagos to discontinue clinical development. The company said it will decide whether to develop the drug in alternative medical indications, and that more details about the ORIGIN study will be released later this year. Ulcerative colitis is a chronic, gastrointestinal disorder involving the rectum and the colon -- the large bowel -- mainly in the mucosa and sub-mucosa gut regions where ulcerations occur. The symptoms can start mild and gradually progress to more severe, with remission periods in between. One of the most commonly reported symptoms is progressive loosening of stool with blood, accompanied by abdominal pain and occasional fever. Loss of appetite, weight loss, and fatigue are not uncommon. Last June, Galapagos announced its Phase 2 proof-of-concept study to evaluate GLPG1205, a GPR84 inhibitor, as a possible therapy for inflammatory bowel diseases (IBD). The GPR84 is a G-coupled protein receptor
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *